Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine As Postoperative Adjuvant Therapy in Patients with EGFR-positive Pancreatic Cancer: a Prospective, Single-arm Study

NCT06722911 is registered in ClinicalTrials.gov with Zhejiang Provincial People's Hospital as lead sponsor.

NCT NCT06722911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06722911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine As Postoperative Adjuvant Therapy in Patients with EGFR-positive Pancreatic Cancer: a Prospective, Single-arm Study
Lead sponsor
Zhejiang Provincial People's Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
November 15, 2024
Completion date
September 30, 2028
Enrollment
57 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer resectable